Annual report pursuant to Section 13 and 15(d)

NATURE OF OPERATIONS

v3.22.0.1
NATURE OF OPERATIONS
12 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
NATURE OF OPERATIONS
1.
NATURE OF OPERATIONS

 

Business

 

Corbus Pharmaceuticals Holdings, Inc. (“the Company” or “Corbus”) is focused on developing new medicines that target inflammation, fibrosis, metabolism and immuno-oncology. Corbus’ current pipeline includes small molecules that activate or inhibit the endocannabinoid system and anti-integrin monoclonal antibodies that block activation of TGFβ. The Company plans to expand its pipeline through internal efforts and business development. Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets and raising capital. The Company’s business is subject to significant risks and uncertainties and the Company will be dependent on raising substantial additional capital before it becomes profitable and it may never achieve profitability.

 

The Company is continuing to monitor the impact of the COVID-19 pandemic on its business and operations.